MaxCyte Revenue and Competitors
Estimated Revenue & Valuation
- MaxCyte's estimated annual revenue is currently $32.3M per year.
- MaxCyte received $1.7M in venture funding in December 2014.
- MaxCyte's estimated revenue per employee is $233,768
- MaxCyte's total funding is $31.3M.
- MaxCyte's current valuation is $793.5M. (January 2022)
Employee Data
- MaxCyte has 138 Employees.
- MaxCyte grew their employee count by 15% last year.
MaxCyte's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP Regulatory | Reveal Email/Phone |
3 | EVP - Global Sales & Marketing | Reveal Email/Phone |
4 | VP, Technical Applications & Customer Support | Reveal Email/Phone |
5 | EVP Administration | Reveal Email/Phone |
6 | EVP, General Counsel | Reveal Email/Phone |
7 | SVP | Global Marketing | Reveal Email/Phone |
8 | SVP, Business Development | Reveal Email/Phone |
9 | EVP Manufacturing and Engineering Operations | Reveal Email/Phone |
10 | VP Regulatory | Reveal Email/Phone |
MaxCyte Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | N/A | 19337 | 4% | N/A | N/A |
What Is MaxCyte?
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top 10 global biopharmaceutical companies, and has more than 55 partnered program licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.
keywords:Biotechnology
$31.3M
Total Funding
138
Number of Employees
$32.3M
Revenue (est)
15%
Employee Growth %
$793.5M
Valuation
N/A
Accelerator
MaxCyte News
About MaxCyte MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based...
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based...
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based...
Nkarta to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its oncology cell-therapy candidates SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of ...
MaxCyte, Inc. ('MaxCyte' or the 'Company') MaxCyte Reports Final Results for the Year Ended 31 December 2020 Gaithersburg, Maryland -20 April 2021:MaxCyte (LSE: MXCT, MXCL, MXCN),a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today annou ...
Other Companies in Gaithersburg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $33.8M | 139 | 4% | N/A |
#2 | $39.3M | 143 | 28% | N/A |
#3 | $48.8M | 144 | -43% | N/A |
#4 | $16.4M | 149 | 10% | N/A |
#5 | $45.1M | 152 | 1% | N/A |
MaxCyte Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2002-12-19 | $1.8M | A | Article | |
| 2004-03-25 | $10.7M | B | Intersouth Partners | Article |
| 2014-12-19 | $1.7M | Undisclosed | Article |